TY - JOUR
T1 - Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection
AU - Kumata, Ryuichi
AU - Iwanami, Shoya
AU - Mar, Katrina B.
AU - Kakizoe, Yusuke
AU - Misawa, Naoko
AU - Nakaoka, Shinji
AU - Koyanagi, Yoshio
AU - Perelson, Alan S.
AU - Schoggins, John W.
AU - Iwami, Shingo
AU - Sato, Kei
N1 - Funding Information:
This study was supported in part by AMED J-PRIDE 19fm0208006 (to S.I.), 19fm0208014 (to S.I.), 19fm0208019 (to S.I.), 19fm0208006 (K.S.); AMED Research Program on HIV/AIDS 19fk0410014 (to Y.Koyanagi and K.S.), 19fk0410023 (to S.I.), 19fk0410019 (to K.S.); AMED Japan Program for Infectious Diseases Research and Infrastructure, 20wm0325007, 20wm0325004, 20wm0325012, 20wm0325015 (to S.I.); Research Program on Emerging and Reemerging Infectious Diseases 19fk0108156 (to S. I.), 20fk0108140 (to S.I.), 20fk0108413 (to S.I.), 20fk0108146 (to K.S.), 19fk0108171 (to K.S.), 20fk0108270 (to Y.Koyanagi and K.S.); Program for Basic and Clinical Research on Hepatitis 19fk0210036 (to S.I.); Program on the Innovative Development and the Application of New Drugs for Hepatitis B 19fk0310114 (to S.I.); AMED CREST 19gm1310002 (to S.I.); Moonshot R&D Grant Number JPMJMS2021 (to S.I.) and JPMJMS2025 (to S.I.); JST PRESTO (to S.N.); JST MIRAI (to S.N. and S.I.); JST CREST (to S.I. and K.S.) including AIP Challenge Program (to R.K.); Grants-in-Aid for Scientific Research (KAKENHI) Scientific Research B 15H05707 (to S.N.), 18KT0018 (to S.I.), 18H01139 (to S.I.), 16H04845 (to S.I.), 18H02662 (to K.S.), Scientific Research on Innovative Areas 20H05042 (to S.I.), 19H04839 (to S.I.), 18H05103 (to S.I.), 16H06429 (to K.S.), 16K21723 (to K.S.), 17H05813 (to K.S.), and 19H04826 (to K.S.), Grant-in-Aid for JSPS Fellows 21J21542 (to R.K.), and Fund for the Promotion of Joint International Research (Fostering Joint International Research) 18KK0447 (to K.S.); Mitsui Life Social Welfare Foundation (to S.I.); Shin-Nihon of Advanced Medical Research (to S.I.); Suzuken Memorial Foundation (to S.I.); Life Science Foundation of Japan (to S.I.); SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation (to S.I.); Toyota Physical and Chemical Research Institute (to S.I.); Takeda Science Foundation (to K. S.); ONO Medical Research Foundation (to K.S.); Ichiro Kanehara Foundation (to K.S.); Lotte Foundation (to K.S.); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K.S.); Daiichi Sankyo Foundation of Life Science (to K.S.); Sumitomo Foundation (to K. S.); Uehara Foundation (to K.S.); Joint Research Project of the Institute of Medical Science, the University of Tokyo (to Y.Koyanagi); Joint Usage/ Research Center program of Institute for Frontier Life and Medical Sciences, Kyoto University (to K. S.); JSPS Core-to-Core program (A. Advanced Research Networks) (to Y.Koyanagi and K.S.); International Joint Research Project of the Institute of Medical Science, the University of Tokyo 2020-K3003 (to K.S.); the U.S. National Institutes of Health (NIH) grants R01AI028433, R01OD011095 (to A.S.P.), AI117922 (to J.W.S.); and The American Lung Association (K.B.M. and J.W.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank Frank Kirchhoff and Daniel Sauter (Ulm University, Germany) for kindly providing the IMCs of HIV-1 CH077_TF and CH077_CC and Sam Wilson (MRC-University of Glasgow Centre for Virus Research, Scotland, UK) for kindly providing the expression plasmid for LY6E. We also thank Kotubu Misawa for dedicated support. We also thank Nora-Guadalupe Ramirez for her technical advice on CRISPR/Cas9 in Jurkat cells.
Publisher Copyright:
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
PY - 2022/4
Y1 - 2022/4
N2 - In HIV-1-infected individuals, transmitted/founder (TF) virus contributes to establish new infection and expands during the acute phase of infection, while chronic control (CC) virus emerges during the chronic phase of infection. TF viruses are more resistant to interferon-alpha (IFN-α)-mediated antiviral effects than CC virus, however, its virological relevance in infected individuals remains unclear. Here we perform an experimental-mathematical investigation and reveal that IFN-α strongly inhibits cell-to-cell infection by CC virus but only weakly affects that by TF virus. Surprisingly, IFN-α enhances cell-free infection of HIV-1, particularly that of CC virus, in a virus-cell density-dependent manner. We further demonstrate that LY6E, an IFN-stimulated gene, can contribute to the density-dependent enhancement of cell-free HIV-1 infection. Altogether, our findings suggest that the major difference between TF and CC viruses can be explained by their resistance to IFN-α-mediated inhibition of cell-to-cell infection and their sensitivity to IFN-α-mediated enhancement of cell-free infection.
AB - In HIV-1-infected individuals, transmitted/founder (TF) virus contributes to establish new infection and expands during the acute phase of infection, while chronic control (CC) virus emerges during the chronic phase of infection. TF viruses are more resistant to interferon-alpha (IFN-α)-mediated antiviral effects than CC virus, however, its virological relevance in infected individuals remains unclear. Here we perform an experimental-mathematical investigation and reveal that IFN-α strongly inhibits cell-to-cell infection by CC virus but only weakly affects that by TF virus. Surprisingly, IFN-α enhances cell-free infection of HIV-1, particularly that of CC virus, in a virus-cell density-dependent manner. We further demonstrate that LY6E, an IFN-stimulated gene, can contribute to the density-dependent enhancement of cell-free HIV-1 infection. Altogether, our findings suggest that the major difference between TF and CC viruses can be explained by their resistance to IFN-α-mediated inhibition of cell-to-cell infection and their sensitivity to IFN-α-mediated enhancement of cell-free infection.
UR - http://www.scopus.com/inward/record.url?scp=85128821983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128821983&partnerID=8YFLogxK
U2 - 10.1371/journal.pcbi.1010053
DO - 10.1371/journal.pcbi.1010053
M3 - Article
C2 - 35468127
AN - SCOPUS:85128821983
SN - 1553-734X
VL - 18
JO - PLoS Computational Biology
JF - PLoS Computational Biology
IS - 4
M1 - e1010053
ER -